samedan logo
 
 
spacer
home > pmps > spring 2012 > setting the scene
PUBLICATIONS

 

Dear guest!
To access full content of this article, please take a minute to become a member of this site. As a registered user you will be able to view all of our vast archive's material at any time. Sign up now!

       Already registered? Please sign in.

Alternatively, please use our pay-per-view service.

spacer

 
News and Press Releases

MultiOmic Health and Mesh Bio Partner to Use AI to Develop Precision Medicines and Diagnostics for Chronic Metabolic Disease

London, UK, and Singapore, 30th June 2022: / Sciad Newswire / MultiOmic Health, an artificial intelligence (AI)-enabled drug discovery company, and Mesh Bio, a digital health startup transforming chronic disease management through predictive analytics, today announce their partnership to conduct an observational clinical study on patients with chronic metabolic disease and increased risk of complications such as chronic kidney disease. The partnership will provide access to data from patient populations in Asia that have historically been underrepresented in chronic metabolic disease studies.
More info >>

 
©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement